YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell–Inflamed Phenotype

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study

(2019) Hyun Cheol Chung et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

(2019) Neal E. Ready et al.   Journal of Thoracic Oncology

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

(2019) Luis Paz-Ares et al.   LANCET

Systems-level network modeling of Small Cell Lung Cancer subtypes identifies master regulators and destabilizers

(2019) David J. Wooten et al.   PLoS Computational Biology

POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer

(2018) Yu-Han Huang et al.   GENES & DEVELOPMENT

Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors

(2018) Julie George et al.   Nature Communications

Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)

(2018) Patrick Danaher et al.   Journal for ImmunoTherapy of Cancer

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer-testis antigens: Unique cancer stem cell biomarkers and targets for cancer therapy

(2018) Olga Gordeeva   SEMINARS IN CANCER BIOLOGY

Cancer/testis antigens (CTAs) expression in resected lung cancer

(2018) Shi Jin et al.   OncoTargets and Therapy

T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

(2018) Patrick A. Ott et al.   JOURNAL OF CLINICAL ONCOLOGY

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

(2017) Mark Ayers et al.   JOURNAL OF CLINICAL INVESTIGATION

Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer

(2017) Karen McColl et al.   Oncotarget

Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicine

(2016) Zhou Zhu et al.   BMC GENOMICS

YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer

(2016) Masafumi Horie et al.   CANCER SCIENCE

ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs

(2016) Mark D. Borromeo et al.   Cell Reports

A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer

(2015) T. K. Owonikoko et al.   CLINICAL CANCER RESEARCH

Comprehensive genomic profiles of small cell lung cancer

(2015) Julie George et al.   NATURE

DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2

(2015) J T Poirier et al.   ONCOGENE

The immune contexture of primary and metastatic human tumours

(2014) Nicolas A Giraldo et al.   CURRENT OPINION IN IMMUNOLOGY

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

(2012) Charles M Rudin et al.   NATURE GENETICS

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

(2012) Martin Peifer et al.   NATURE GENETICS

Long-Term Survival for Patients With Non–Small-Cell Lung Cancer With Intratumoral Lymphoid Structures

(2008) Marie-Caroline Dieu-Nosjean et al.   JOURNAL OF CLINICAL ONCOLOGY